Zheng et al. used CAR T and TRP-1 T cells as a high-efficiency carrier to systemically deliver the myxoma virus (MYXV) to homologous antigen-expressing tumors (CAR/TCR-T10%MYXV), inducing specific tumor cell death, autophagy, and showing a potent form of bystander killing that eradicates antigen-negative tumor cells that contribute to tumor elimination and adaptive immunity with suppressed antigen escape.299 Bispecific CAR T cells were also loaded with VSVm-IFNβ or reovirus to treat B16/CT2AEGFRvIII tumor-bearing mice. This evidence concerns the gene IFNB1 and neoplasm.